[Pharmacological profile and clinical findings of Maraviroc (Celsentri® Tablets)].
masanori.hizue@pfizer.com
Masanori
M
Hizue
D000818:Animals; D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D015704:CD4 Antigens / Q000378:metabolism; D002986:Clinical Trials as Topic; D003510:Cyclohexanes / Q000008:administration & dosage* / Q000494:pharmacology*; D024882:Drug Resistance, Viral; D015699:HIV Envelope Protein gp120 / Q000378:metabolism; D015658:HIV Infections / Q000188:drug therapy* / Q000821:virology; D015497:HIV-1 / Q000187:drug effects; D006801:Humans; D000077592:Maraviroc; D011485:Protein Binding; D013607:Tablets; D014230:Triazoles / Q000008:administration & dosage* / Q000494:pharmacology*
D019380:Anti-HIV Agents; D065100:CCR5 Receptor Antagonists; D015704:CD4 Antigens; D003510:Cyclohexanes; D015699:HIV Envelope Protein gp120; D013607:Tablets; D014230:Triazoles; C514793:gp120 protein, Human immunodeficiency virus 1; D000077592:Maraviroc